A 69024

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571156

CAS#: 58939-37-0

Description: A 69024 is a highly selective dopamine D-1 receptor antagonist. It is a radioligand that may antagonize self-mutilatory behavior.

Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-03-29. Prices are subject to change without notice.

A 69024 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 571156
Name: A 69024
CAS#: 58939-37-0
Chemical Formula: C20H24BrNO4
Exact Mass: 421.0889
Molecular Weight: 422.32
Elemental Analysis: C, 56.88; H, 5.73; Br, 18.92; N, 3.32; O, 15.15

Synonym: A 69024; A-69024; A69024; A 66359; A-66359; A66359

IUPAC/Chemical Name: 7-Isoquinolinol, 1-((2-bromo-4,5-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-


InChi Code: InChI=1S/C20H24BrNO4/c1-22-6-5-12-8-18(24-2)17(23)10-14(12)16(22)7-13-9-19(25-3)20(26-4)11-15(13)21/h8-11,16,23H,5-7H2,1-4H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Kassiou M, Loc'h C, Bottlaender M, Mardon K, Ottaviani M, Coulon C, Katsifis A, Maziere B. (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol. 2002 Apr;29(3):295-302. PubMed PMID: 11929698.

2: Kassiou M, Mardon K, Mattner F, Katsifis A, Dikic B. Pharmacological evaluation of (+)-2- [123I]A-69024: a radioligand for in vivo studies of dopamine D1 receptors. Life Sci. 2001 Jun 29;69(6):669-75. PubMed PMID: 11476188.

3: Kerkman DJ, Ackerman M, Artman LD, MacKenzie RG, Johnson MC, Bednarz L, Montana W, Asin KE, Stampfli H, Kebabian JW. A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor. Eur J Pharmacol. 1989 Aug 3;166(3):481-91. PubMed PMID: 2509217.

4: Criswell HE, Mueller RA, Breese GR. Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors. Neuropsychopharmacology. 1992 Sep;7(2):95-103. PubMed PMID: 1418306.

5: Kassiou M, Scheffel U, Ravert HT, Mathews WB, Musachio JL, Lambrecht RM, Dannals RF. [11C]A-69024: a potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nucl Med Biol. 1995 Feb;22(2):221-6. PubMed PMID: 7767316.

6: Besret L, Dollé F, Hérard AS, Guillermier M, Demphel S, Hinnen F, Coulon C, Ottaviani M, Bottlaender M, Hantraye P, Kassiou M. Dopamine D1 receptor imaging in the rodent and primate brain using the isoquinoline +-[11C]A-69024 and positron emission tomography. J Pharm Sci. 2008 Jul;97(7):2811-9. PubMed PMID: 17786986.

7: Kassiou M, Scheffel UA, Musachio JL, Stathis M, Dannals RF. [3H]A-69024: a non-benzazepine ligand for in vitro and in vivo studies of dopamine D1 receptors. Life Sci. 1995;57(23):PL367-72. PubMed PMID: 7475960.

8: Daly SA, Waddington JL. Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur J Pharmacol. 1992 Mar 24;213(2):251-8. PubMed PMID: 1387846.

9: Smith AD, Smith DL, Zigmond MJ, Amalric M, Koob GF. Differential effects of dopamine receptor subtype blockade on performance of rats in a reaction-time paradigm. Psychopharmacology (Berl). 2000 Mar;148(4):355-60. PubMed PMID: 10928307.

10: Shippenberg TS, Bals-Kubik R, Huber A, Herz A. Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology (Berl). 1991;103(2):209-14. PubMed PMID: 1827526.

11: Witkin JM, Newman AH, Nowak G, Katz JL. Role of dopamine D1 receptors in the lethal effects of cocaine and a quaternary methiodide analog. J Pharmacol Exp Ther. 1993 Oct;267(1):266-74. PubMed PMID: 7901394.

12: Katz JL, Kopajtic TA, Myers KA, Mitkus RJ, Chider M. Behavioral effects of cocaine: interactions with D1 dopaminergic antagonists and agonists in mice and squirrel monkeys. J Pharmacol Exp Ther. 1999 Oct;291(1):265-79. PubMed PMID: 10490913.

13: Lappalainen J, Hietala J, Pohjalainen T, Syvälahti E. Regulation of dopamine D1 receptors by chronic administration of structurally different D1 receptor antagonists: a quantitative autoradiographic study. Eur J Pharmacol. 1992 Jan 14;210(2):195-200. PubMed PMID: 1534766.

14: Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther. 1995 Apr;273(1):101-12. PubMed PMID: 7714755.

15: Daly SA, Waddington JL. New classes of selective D-1 dopamine receptor antagonist provide further evidence for two directions of D-1:D-2 interaction. Neurochem Int. 1992 Mar;20 Suppl:135S-139S. Review. PubMed PMID: 1365412.

16: Britton DR, Curzon P, Mackenzie RG, Kebabian JW, Williams JE, Kerkman D. Evidence for involvement of both D1 and D2 receptors in maintaining cocaine self-administration. Pharmacol Biochem Behav. 1991 Aug;39(4):911-5. PubMed PMID: 1684870.

17: Rice OV, Gatley SJ, Shen J, Huemmer CL, Rogoz R, DeJesus OT, Volkow ND, Gifford AN. Effects of endogenous neurotransmitters on the in vivo binding of dopamine and 5-HT radiotracers in mice. Neuropsychopharmacology. 2001 Nov;25(5):679-89. PubMed PMID: 11682251.

18: Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate. Psychopharmacology (Berl). 1995 Feb;117(4):403-12. PubMed PMID: 7604140.